• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Texas Heart Institute, TAMU receive $3m for biotechnology center

Texas Heart Institute, TAMU receive $3m for biotechnology center

September 18, 2013
CenterWatch Staff

The Texas Heart Institute (THI) and Texas A&M University (TAMU) College of Veterinary Medicine and Biomedical Sciences have received a $3 million grant through the Texas Emerging Technology Fund (TETF) to create the Center for Cell and Organ Biotechnology

TAMU houses the Michael E. DeBakey Institute for Comparative Cardiovascular Science and Biomedical Devices, which is known for biomedical research programs in vascular studies and cardiovascular devices. At the DeBakey Institute, cardiovascular scientists, engineers and clinicians from TAMU and the UT Medical School in Houston will collaborate on cardiovascular disease in both human and veterinary patients.

In the U.S., one in three individuals suffer from some form of cardiovascular disease and more than one million die from end-stage organ failure each year. The new center will take a multi-faceted approach to chronic disease for both human and veterinary health care, based on cell and organ failure.

The center will be led by Dr. Doris Taylor, director, Regenerative Medicine Research, Texas Heart Institute and will include scientists, engineers, physicians, veterinarians and business managers from both THI and the TAMU.

The TETF is a $200 million initiative created by the Texas Legislature in 2005 at the governor’s request to provide Texas with an advantage in the research, development and commercialization of emerging technologies, and reauthorized in 2007, 2009, 2011 and 2013. A 17-member advisory committee of entrepreneurs and research experts reviews potential projects and recommends funding allocations to the governor, lieutenant governor and speaker of the house. To date, the TETF has allocated more than $203 million in funds to 142 early stage companies, and over $216 million in grant matching and research superiority funds to Texas universities.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing